Actively Recruiting
Genotype-Phenotype Relationship Between Adult Cryptogenic Cholestasis and Mutations in Genes Responsible for Progressive Familial Intrahepatic Cholestasis
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-01-17
300
Participants Needed
2
Research Sites
34 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the relationship between gene mutations and adult cryptogenic cholestasis, a type of cholestatic liver disease. This study focuses on mutations in genes responsible for progressive familial intrahepatic cholestasis (PFIC). The goal is to better understand how these gene mutations relate to different clinical presentations, identify risk factors, and eventually support personalized treatments for affected patients. This is a multicenter, retrospective observational study collecting data on patients diagnosed with cholestatic liver diseases, including PFIC, cryptogenic cholestatic liver diseases (CCLDs), and hepatobiliary cancer (HBC). Diagnoses are confirmed through imaging studies, and cases with other known liver disease causes are excluded. The study gathers existing patient data from May 2013 until the study start date. Participants will have their gene mutations classified and clinical and histological outcomes assessed over a 12-month period. Researchers will evaluate mutation types in PFIC genes and observe related clinical features and liver tissue patterns. Data collection involves reviewing patient records and diagnostic imaging. Safety monitoring is not applicable as this is an observational study with no interventions, and participant involvement focuses on data review.
CONDITIONS
Brief Title
Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of progressive familial intrahepatic cholestasis, cryptogenic cholestatic liver diseases, or hepatobiliary cancer
- Ability to provide informed consent
You will not qualify if you...
- Presence of another documented chronic liver disease that explains the clinical phenotype
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants with cholestatic liver diseases are observed to gather information on genetic mutations and clinical presentations.
Data collection occurs retrospectively from May 2013 until study start; no additional visits are required.
Trial Site Locations
Total: 2 locations
1
IRCCS - Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
2
Ospedale Civile Sant'Agostino Estense Baggiovara
Modena, Modena, Italy, 41126
Actively Recruiting
Research Team
G
Giovanni Vitale, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here